Key Dates

Related Announcements

PAR-22-111 - Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed)

Issued by

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Purpose

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) announces the early termination of PAR-22-111, “Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed)”. NIDDK will not accept applications in response to PAR-22-111 for the July 14, 2023 submission date or any subsequent submission dates.

This Notice does not affect applications in response to these funding opportunities that have already been reviewed. Applications reviewed for FY 2023 funding will be selected for funding using standard NIDDK procedures. For grants that already have been awarded, NIDDK plans to continue support for non-competing awards in future years.

Inquiries

Please direct all inquiries to:

For Division of Diabetes, Endocrinology and Metabolic Diseases-related inquiries:

Yan Li, Ph.D. 
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 
Telephone: 301-435-3721 
Email: [email protected] 

For Division of Digestive Diseases and Nutrition-related inquiries:

Bonnie Burgess-Beusse, Ph.D.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 
Telephone: 301-594-4726 
Email: [email protected] 

For Division of Kidney, Urologic, and Hematologic-related inquiries:

Anna Sadusky, Ph.D. 
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 
Telephone: 301-827-7036 
Email: [email protected]